Maged Shenouda bought $1.1M of Relmada Therapeutics (RLMD)
Executed Nov 5 2025, disclosed Nov 6 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Nov 6 2025), the stock returned +48.8% (delay-adjusted); from the execution session (Nov 5 2025), +56.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Maged Shenouda (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 1 priced purchase filing, the average 21-session return was +56.9% from execution and +48.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of RLMD (500,000 sh × $2.20, as filed), executed Nov 5 2025.
Healthcare · Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→200,000 sh across 2 lots
Exec Sep 9
Filed Sep 11 · 7:30 AM ET